Loading...
XNASPACB
Market cap575mUSD
Jan 10, Last price  
2.10USD
1D
0.00%
1Q
6.06%
Jan 2017
-44.74%
IPO
-87.63%
Name

Pacific Biosciences of California Inc

Chart & Performance

D1W1MN
XNAS:PACB chart
P/E
P/S
2.87
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
13.43%
Rev. gr., 5y
20.59%
Revenues
201m
+56.29%
2,163,000901,000135,0001,674,00033,863,00025,983,00028,181,00060,594,00092,782,00090,714,00093,468,00078,626,00090,891,00078,893,000130,513,000128,304,000200,521,000
Net income
-307m
L+3.30%
-21,518,000-43,754,000-87,703,000-140,166,000-109,388,000-94,465,000-79,293,000-66,160,000-31,696,000-74,375,000-92,189,000-102,562,000-77,819,00029,403,000-181,223,000-296,930,000-306,735,000
CFO
-259m
L-1.53%
-16,732,000-38,303,000-74,838,000-121,996,000-102,974,000-76,822,000-29,833,000-51,468,000-47,889,000-67,929,000-67,518,000-66,430,000-78,312,00019,503,000-111,180,000-263,211,000-259,173,000
Earnings
Feb 13, 2025

Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
IPO date
Oct 27, 2010
Employees
769
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
200,521
56.29%
128,304
-1.69%
Cost of revenue
334,911
272,269
Unusual Expense (Income)
NOPBT
(134,390)
(143,965)
NOPBT Margin
Operating Taxes
(11,424)
(17,318)
Tax Rate
NOPAT
(122,966)
(126,647)
Net income
(306,735)
3.30%
(296,930)
63.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
189,200
11,230
BB yield
-7.60%
-0.61%
Debt
Debt current
10,081
10,728
Long-term debt
965,046
996,595
Deferred revenue
5,530
1,794
Other long-term liabilities
20,301
178,833
Net debt
331,711
232,083
Cash flow
Cash from operating activities
(259,173)
(263,211)
CAPEX
(8,843)
(16,929)
Cash from investing activities
4,604
116,083
Cash from financing activities
108,891
9,622
FCF
(123,063)
(142,137)
Balance
Cash
631,416
772,318
Long term investments
12,000
2,922
Excess cash
633,390
768,825
Stockholders' equity
(1,838,588)
(1,536,878)
Invested Capital
3,499,653
3,237,776
ROIC
ROCE
EV
Common stock shares outstanding
253,629
224,550
Price
9.81
19.93%
8.18
-60.02%
Market cap
2,488,100
35.46%
1,836,819
-56.02%
EV
2,819,811
2,068,902
EBITDA
(107,856)
(126,647)
EV/EBITDA
Interest
14,343
14,690
Interest/NOPBT